| scholarly article | Q13442814 |
| P50 | author | Stephen Swisher | Q89454225 |
| Wayne L. Hofstetter | Q107450763 | ||
| Ara A Vaporciyan | Q107455112 | ||
| David C Rice | Q107459437 | ||
| Kazuki Sudo | Q60633530 | ||
| Jaffer Ajani | Q64913003 | ||
| P2093 | author name string | A Suzuki | |
| J H Lee | |||
| L Xiao | |||
| M S Bhutani | |||
| S H Lin | |||
| J Welch | |||
| D M Maru | |||
| M A Blum | |||
| T Taketa | |||
| N K S Cheedella | |||
| P2860 | cites work | Esophageal and esophagogastric junction cancers | Q84909377 |
| Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy | Q85026153 | ||
| Global cancer statistics | Q22241238 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Environmental causes of esophageal cancer | Q28388848 | ||
| Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy | Q35129698 | ||
| Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. | Q36495076 | ||
| Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. | Q36841557 | ||
| Chemoradiation in the management of esophageal cancer | Q36935105 | ||
| Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation | Q37320833 | ||
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 | ||
| Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer | Q43038423 | ||
| The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma | Q43593864 | ||
| Worldwide esophageal cancer collaboration | Q44185301 | ||
| Population attributable risks of esophageal and gastric cancers | Q44586583 | ||
| A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma | Q44902232 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. | Q53197682 | ||
| Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. | Q53665053 | ||
| Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 | ||
| Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report | Q70736020 | ||
| A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus | Q72313681 | ||
| Geographical distribution and racial disparity in esophageal cancer | Q79124963 | ||
| Esophageal cancer | Q79620977 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| P433 | issue | 5 | |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| gastroesophageal cancer | Q61913382 | ||
| P304 | page(s) | 1262-1266 | |
| P577 | publication date | 2012-12-17 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort | |
| P478 | volume | 24 |
| Q37625131 | ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. |
| Q38161349 | Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis |
| Q92184392 | CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy |
| Q42362312 | Cancer of the esophagus and esophagogastric junction: an 8th edition staging primer |
| Q37578945 | Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae |
| Q88964291 | Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study |
| Q35842037 | Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications |
| Q47120642 | Editorial on "Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer". |
| Q49566998 | Endoscopic and Imaging Predictors of Complete Pathologic Response After Chemoradiation for Esophageal Cancer |
| Q59482283 | Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery |
| Q34332847 | Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. |
| Q36897515 | Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma |
| Q51500331 | Intraoperative and postoperative risk factors for anastomotic leakage and pneumonia after esophagectomy for cancer. |
| Q47134855 | Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm? |
| Q55437617 | Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. |
| Q33882085 | Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer |
| Q98159769 | Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation |
| Q28086781 | Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment |
| Q41202499 | Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials |
| Q38669772 | Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. |
| Q91326735 | Oesophageal preservation in locally advanced oesophageal cancer |
| Q47102453 | On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: additional evaluation by magnetic resonance imaging may help |
| Q47275072 | Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience |
| Q64940253 | Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. |
| Q51625158 | Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy. |
| Q47108211 | Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update |
| Q91925730 | Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study |
| Q55230734 | Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation. |
| Q51050086 | Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy. |
| Q64994548 | The emerging field of radiomics in esophageal cancer: current evidence and future potential. |
| Q38234184 | The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies |
| Q37277133 | Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern |
| Q26798220 | Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival |
| Q92573193 | Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma |
| Q38817844 | What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? |
Search more.